IGF-1 DES

PRODUCT OVERVIEW

Specification	Details
Generic Name	IGF-1 DES
Drug Class	IGF-1 Analog
Active Ingredient	Des(1-3) IGF-1
Administration Route	Injectable Research Peptide
Dosage Form	Injectable Peptide
Chemical Class	Modified Insulin-Like Growth Factor-1 Analog
Primary Target	IGF-1 Receptor (IGF-1R)
Clinical Status	Investigational; not approved as a therapeutic medication

INTRODUCTION

IGF-1 DES, also known as Des(1-3) IGF-1, is a modified analog of human Insulin-Like Growth Factor-1 (IGF-1). The designation "DES" refers to the deletion of the first three amino acids from the N-terminal region of native IGF-1.

This structural modification alters the interaction of the peptide with IGF-binding proteins and can increase its biological availability in experimental systems. IGF-1 DES is primarily used as a research tool for investigating IGF-1 receptor signaling, cellular growth, protein synthesis, and tissue-specific biological responses.

HISTORY

IGF-1 DES emerged from research examining how structural modifications of native IGF-1 affect receptor activity and interaction with IGF-binding proteins. Studies of truncated IGF-1 variants demonstrated that removal of the N-terminal amino acids could substantially alter binding characteristics while retaining biological activity at the IGF-1 receptor.

This research contributed to a broader understanding of how IGF-1 structure regulates its biological availability and activity. IGF-1 DES remains an experimental peptide and has not been developed as an approved therapeutic medication.

CHEMICAL STRUCTURE

IGF-1 DES is a truncated analog of human IGF-1 in which the first three amino acids of the native peptide are removed.

The modification results in:

- Deletion of residues 1–3
- Retention of the majority of the native IGF-1 structure
- Altered interaction with IGF-binding proteins
- Preservation of biological activity at the IGF-1 receptor

CHEMICAL PROFILE

Parameter	Information
Primary Components	IGF-1 DES
Hormone Classification	IGF-1 Analog
Administration	Injectable Research Peptide
Dosage Form	Injectable Peptide
Molecular Type	Modified Peptide
Structural Modification	N-terminal deletion of amino acids 1–3

PHARMACOLOGY

IGF-1 DES exerts its biological activity primarily through the IGF-1 receptor (IGF-1R). Activation of this receptor initiates intracellular signaling pathways involved in cellular growth, protein synthesis, metabolism, and survival.

Major signaling pathways associated with IGF-1 receptor activation include:

- PI3K/Akt
- MAPK/ERK
- mTOR-related signaling
- Cellular growth and survival pathways

MECHANISM OF ACTION

The general mechanism involves:

- Administration of the modified peptide
- Systemic distribution
- Binding to IGF-1 receptors
- Receptor activation
- Intracellular signal transduction
- Activation of PI3K/Akt and MAPK pathways
- Regulation of protein synthesis and cellular growth
- Modulation of tissue-specific biological processes

PHARMACODYNAMICS

IGF-1 signaling may influence:

• Protein synthesis • Muscle-cell growth • Satellite-cell activity • Cellular regeneration • Tissue remodeling

SKELETAL MUSCLE SYSTEM

Anabolic-androgenic steroids interact with androgen receptors in skeletal muscle and may influence:

- Protein metabolism
- Muscle tissue maintenance
- Nitrogen metabolism
- Muscle cell function

Androgen receptor signaling contributes to the regulation of normal skeletal muscle structure and function.

SKELETAL SYSTEM

Androgen receptor signaling contributes to skeletal physiology and may influence:

- Bone remodeling
- Skeletal maintenance
- Bone metabolism
- Structural integrity

CONNECTIVE TISSUE

Androgen receptor signaling may influence connective tissue physiology through:

- Structural protein metabolism
- Tissue maintenance
- Tissue remodeling
- Collagen metabolism

REPRODUCTIVE SYSTEM

Androgenic compounds interact with androgen-sensitive tissues and may influence:

- Hormonal regulation
- Endocrine signaling
- Reproductive physiology
- Androgen-responsive tissues

PHARMACOKINETICS

The pharmacokinetic characteristics of IGF-1 DES have not been comprehensively established in controlled human clinical studies.

Removal of the first three amino acids changes the peptide's interaction with IGF-binding proteins compared with native IGF-1. This can increase the fraction of biologically available peptide in experimental systems.

Because IGF-1 DES is an investigational peptide rather than an approved medicine, standardized human pharmacokinetic parameters such as therapeutic half-life, clearance, and bioavailability have not been established.

PHYSIOLOGICAL EFFECTS

IGF-1 DES produces biological activity through the IGF-1 receptor and influences signaling pathways associated with protein synthesis, cellular growth, survival, and tissue remodeling. Its structural modification reduces interaction with certain IGF-binding proteins compared with native IGF-1, potentially increasing receptor availability in experimental environments. IGF-1 signaling is relevant to skeletal muscle, bone, cartilage, connective tissue, and cellular metabolism.

Because IGF-1 receptors are widely distributed throughout the body, activation can affect multiple physiological systems. These pathways also participate in glucose regulation and cellular proliferation, meaning that excessive or uncontrolled IGF-1 signaling may produce effects beyond localized tissue responses. The physiological effects of IGF-1 DES in humans have not been adequately characterized through controlled clinical research.

CLINICAL APPLICATIONS

IGF-1 DES has no established approved clinical application. Its principal role is as an experimental research peptide used to investigate IGF-1 receptor signaling, cellular growth, protein metabolism, and tissue biology.

Research involving the broader IGF-1 pathway has applications in the study of growth disorders, muscle physiology, bone metabolism, metabolic disease, and tissue repair. However, these research areas should not be interpreted as established therapeutic indications for IGF-1 DES itself.

SAFETY CONSIDERATIONS

The use of anabolic-androgenic steroids may require consideration of cardiovascular, hematological, hepatic, endocrine, metabolic, and reproductive health.

Important safety considerations include:

- Cardiovascular health
- Blood pressure
- Hematological parameters
- Lipid profile
- Liver function
- Endocrine function
- Reproductive function
- Prostate health

The overall safety profile depends on the specific compound, formulation, concentration, duration of exposure, individual response, and patient characteristics. Appropriate medical evaluation and regular monitoring should be considered when clinically indicated.

POTENTIAL ADVERSE EFFECTS

Potential adverse effects associated with anabolic-androgenic steroid exposure may involve endocrine, cardiovascular, hematological, hepatic, dermatological, reproductive, and metabolic systems.

Endocrine Effects
- Suppression of endogenous hormone production
- Alterations in hormonal balance
- Changes in reproductive hormone signaling
- Potential suppression of spermatogenesis

Cardiovascular Effects
- Changes in lipid profile
- Possible increases in blood pressure
- Potential cardiovascular risk

Hematological Effects
- Changes in hematocrit
- Changes in hemoglobin
- Possible increase in erythropoietic activity

Dermatological Effects
- Acne
- Increased sebaceous activity
- Androgen-related hair loss in genetically predisposed individuals

Reproductive Effects
- Changes in reproductive function
- Potential reduction in fertility
- Alterations in reproductive hormone regulation

Hepatic & Metabolic Effects
- Changes in liver function parameters
- Alterations in metabolic markers
- Changes in glucose and lipid metabolism

The occurrence and severity of adverse effects vary according to the specific compound, formulation, exposure, duration of use, individual response, and patient characteristics.

CONTRAINDICATIONS

Condition	Reason
Severe hepatic disease	Increased hepatic risk
Hormone-sensitive cancers	Androgen receptor sensitivity
Pregnancy	Potential risk of fetal development
Known hypersensitivity	Allergic reaction
Significant cardiovascular disease	Potential cardiovascular effects

DRUG INTERACTIONS

A comprehensive interaction profile may not be established for every anabolic-androgenic steroid or formulation.

Potential interactions or clinical considerations may exist with:
- Anticoagulants
- Antidiabetic medications
- Hepatotoxic medications
- Other anabolic-androgenic steroids
- Other hormonal therapies
- Drugs affecting lipid metabolism

The clinical significance of potential interactions depends on the specific compound, formulation, dosage, duration of exposure, concomitant medications, and individual patient characteristics. Appropriate medical evaluation should be considered when multiple medications or hormonal therapies are used concurrently.

LABORATORY MONITORING

Laboratory Test	Purpose
CBC	Monitor hematological parameters
ALT / AST	Liver function
Bilirubin	Hepatic assessment
Lipid Profile	Cardiovascular risk assessment
Blood Pressure	Cardiovascular monitoring
Total Testosterone	Assess androgen status
LH / FSH	Assess endocrine suppression

STORAGE & STABILITY

* Store according to official product labeling.
* Protect from excessive heat and direct sunlight.
* Do not freeze.
* Maintain original packaging integrity.
* Keep away from children.
* Inspect packaging before use.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

* Batch number tracking
* Manufacturing information
* Expiration date verification
* QR authentication system
* Authorized distribution verification

NEXON emphasizes transparency, traceability, and product quality control.

FREQUENTLY ASKED QUESTIONS

What is IGF-1 DES?
IGF-1 DES is a modified and truncated analog of human IGF-1 in which the first three amino acids have been removed.

Is IGF-1 DES a steroid?
No. It is a modified peptide, not an anabolic steroid.

Is IGF-1 DES a SARM?
No. Its primary target is the IGF-1 receptor, not the androgen receptor.

Is IGF-1 DES oral or injectable?
It is encountered as an injectable research peptide and does not have an approved oral dosage form.

What is the primary target of IGF-1 DES?
Its principal target is the IGF-1 receptor (IGF-1R).

Is IGF-1 DES the same as HGH?
No. HGH (somatropin) is growth hormone, whereas IGF-1 DES is a modified analog of IGF-1, a major mediator of growth hormone signaling.

NEXON QUALITY COMMITMENT

NEXON is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

*Kicman AT. Pharmacology of Anabolic Steroids.

* Basaria S. Androgen Abuse in Athletes: Detection and Consequences.

* Handelsman DJ. Androgen Physiology and Pharmacology.

* Shahidi NT. Chemistry, Biological Action and Clinical Applications of Anabolic-Androgenic Steroids.

* Llewellyn W. Anabolics.

* Evans NA. Current Concepts in Anabolic-Androgenic Steroids.

* Kochakian CD. Anabolic-Androgenic Steroids.

* Nieschlag E, Behre HM. Andrology: Male Reproductive Health and Dysfunction.

* Kicman AT, Gower DB. Anabolic Steroids in Sport and Exercise.

* Wilson JD. Androgen Physiology and Pharmacology.